Daniel Nava Rodrigues
YOU?
Author Swipe
View article: BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity Open
The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage plasticity, an…
View article: Development and Validation of a New BAG-1L–Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer
Development and Validation of a New BAG-1L–Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer Open
BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of the androgen receptor, leading to prostate cancer development and progression. Studies investigating the clinical…
View article: Anaesthetic Management of a Foramen Magnum Meningioma Resection Surgery: A Case Report
Anaesthetic Management of a Foramen Magnum Meningioma Resection Surgery: A Case Report Open
The foramen magnum meningioma (FMM) is one of the most threatening tumours among the meningiomas because of its specific location, clinical course, subtle onset, and relatively big dimensions at presentation. Tumour size may mandate carefu…
View article: Supplementary Figure S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplementary Figure S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Consort diagram describing samples disposition in the study.
View article: Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity associating with…
View article: Supplementary Figure S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplementary Figure S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Consort diagram describing samples disposition in the study.
View article: Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Summary of tumor (baseline) and cfDNA (baseline and progression) mutations detected by WES for a patient who responded to Olaparib. New events in TP53 and TSC2 were detected at progression.
View article: Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers
Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers Open
Preclinical studies have demonstrated synergy between PARP and PI3K/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)–deficient and BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective i…
View article: Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Plots showing percentage changes in total cfDNA concentration for each patient at weeks 4 and 8 of treatment, compared to same-patient baseline value. The left plot includes non-responding patients and the right plot includes patients who …
View article: Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Summary of tumor (baseline) and cfDNA (baseline and progression) mutations detected by WES for a patient who responded to Olaparib. New events in TP53 and TSC2 were detected at progression.
View article: Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers
Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers Open
Supplementary Tables 1-7; Supplementary Figures 1-2; Supplementary Methods
View article: Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers
Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers Open
Supplementary Tables 1-7; Supplementary Figures 1-2; Supplementary Methods
View article: Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Plots showing percentage changes in total cfDNA concentration for each patient at weeks 4 and 8 of treatment, compared to same-patient baseline value. The left plot includes non-responding patients and the right plot includes patients who …
View article: Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition Open
Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity associating with…
View article: Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers
Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers Open
Preclinical studies have demonstrated synergy between PARP and PI3K/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)–deficient and BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective i…
View article: Supplementary Table 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Supplementary Table 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity Open
Baseline values at start of abiraterone
View article: Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer Open
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
View article: Table S1 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Table S1 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer Open
Table S1
View article: Figure S1 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification
Figure S1 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification Open
Plotting a) the median spread of coverage per-gene, from the pooled reference data and b) the per-gene standard deviations for duplicated samples shows that some genes are less reliable than others.
View article: Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer Open
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
View article: Data from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification
Data from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification Open
Purpose: Precise detection of copy number aberrations (CNA) from tumor biopsies is critically important to the treatment of metastatic prostate cancer. The use of targeted panel next-generation sequencing (NGS) is inexpensive, high through…
View article: Table S1 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification
Table S1 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification Open
Genomic regions used for the targeted panel sequencing in this study.
View article: Figure S3 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Figure S3 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer Open
Figure S3
View article: Figure S1 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Figure S1 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer Open
Figure S1
View article: Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer Open
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
View article: Supplementary Figure 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Supplementary Figure 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity Open
Sample overview